-

MedsEngine Presents at ESC in London, U.K.

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC is a clinical decision support company that develops software for treating chronic disease. Data was presented on cerebrovascular events and myocardial infarctions in patients treated with MedsEngine-Hypertension at the 2024 European Society of Cardiology Congress in London, U.K.

Hypertension is recognized as a leading cause of atherosclerotic cardiovascular disease and death globally. Data was retrieved from EHRs for a period of seven years for patients with hypertension managed with MedsEngine (average age 61) and patients with normal blood pressure (average age 43). Comparable cerebrovascular and MI events were observed (10/1000 and 4.2/1000 patients, respectively). This observation is noteworthy as it suggests controlling hypertension reduces strokes and MIs to the rate of a non-hypertensive 43-year-old.

Dr. Doug Romer, COO/CMO of MedsEngine, stated, “Utilizing MedsEngine-Hypertension, that incorporates hemodynamic data and a proprietary algorithm to control hypertension, can have a positive impact on the occurrence of strokes and heart disease. MedsEngine has demonstrated blood pressure control rates of 92% (<140/90) for 10 consecutive years.”

MedsEngine will have a booth at the AHA Hypertension Scientific Session in Chicago from September 5-8. Stop by to learn more about the benefits of MedsEngine.

About MedsEngine

MedsEngine develops EHR-integrated clinical decision support applications that generate real-time, personalized, evidence-based medication recommendations for Hypertension, Cholesterol Management, Type 2 Diabetes, and Heart Failure. For more information, visit http://www.medsengine.com.

Contacts

hello@medsengine.com

Industry:

MedsEngine

Release Versions
English

Contacts

hello@medsengine.com

More News From MedsEngine

 HITLAB Validates MedsEngine’s Value in Treating Chronic Diseases

NEW YORK--(BUSINESS WIRE)--HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis usin...

MedsEngine Helps Medical Practices Unlock $30,000 Per Provider in Additional Annual Revenue

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a leader in chronic disease management software, announced today that medical practices using its Cholesterol and Type 2 Diabetes modules could generate up to $30,000 in additional annual revenue. This estimate is based on a typical patient panel of 2,000 and leverages national averages and published financial data related to these chronic conditions. “Using MedsEngine is a win-win for providers and patients,” said Dr. Doug Romer, Chief Medical Officer...

MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits. These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024...
Back to Newsroom